Mean differences and 95% CrI for EGA at delivery (in weeks) from the pairwise and network meta-analyses
| . | Placebo/control | Prostaglandin inhibitors | Magnesium sulfate | Betamimetics | Calcium channel blockers | Nitrates | Oxytocin receptor blockers |
| Placebo/control | 2.32 (1.27 to 3.35) | 1.29 (0.29 to 2.27) | 1.25 (0.40 to 2.07) | 1.69 (0.69 to 2.66) | 1.65 (0.52 to 2.78) | 0.68 (−1.32 to 2.67) | |
| Prostaglandin inhibitors | 3.27 (1.68 to 4.78) | −1.04 (−2.01 to –0.04) | −1.08 (−2.08 to –0.05) | −0.64 (−1.68 to 0.42) | −0.67 (−1.97 to 0.67) | −1.65 (−3.76 to 0.52) | |
| Magnesium sulfate | −0.14 (−1.60 to 1.28) | −0.23 (−1.45 to 0.97) | −0.04 (−0.99 to 0.91) | 0.40 (−0.51 to 1.31) | 0.36 (−0.88 to 1.63) | −0.61 (−2.69 to 1.50) | |
| Betamimetics | 1.91 (0.90 to 2.90) | −1.56 (−3.42 to 0.28) | −0.19 (−2.78 to 2.45) | 0.44 (−0.32 to 1.20) | 0.40 (−0.54 to 1.37) | −0.57 (−2.58 to 1.47) | |
| Calcium channel blockers | na | −0.53 (−2.32 to 1.25) | −0.02 (−1.25 to 1.22) | 0.80 (−0.08 to 1.67) | −0.03 (−1.16 to 1.10) | −1.01 (−2.98 to 0.99) | |
| Nitrates | 0.17 (−1.72 to 2.06) | na | na | −0.58 (−0.47 to 1.67) | 1.30 (−1.07 to 3.68) | −0.98 (−3.15 to 1.21) | |
| Oxytocin receptor blockers | 0.90 (−1.74 to 3.53) | na | na | na | −1.21 (−3.66 to 1.23) | na |
The upper diagonal displays the mean differences for the column intervention vs the row intervention, derived from the NMA. Values >0 favour the column defining intervention. The lower diagonal displays the mean differences for the row intervention vs the column intervention, derived from direct comparisons only. Values >0 favour the row defining the intervention.
Adapted from the National Institute for Health and Care Excellence guideline.13
Crl, credible interval; EGA, estimated gestational age; na, not available; NMA, network meta-analysis.